ScreenerHero

TLPHTalphera Inc. Common Stock

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · talphera.com
1.190USD0.00%Mkt Cap: 61.77M $P/E: —

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized fo…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap61.77M $
Enterprise Value51.19M $
Revenue (TTM)1.00K $
Gross Profit-6.70M $
Net Income (TTM)-14.29M $
Revenue/Share0.0000 USD
Last Price1.190 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees12
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.86
PEG—
EV/EBITDA—
EV/Revenue51190.90
P/S61767.90
P/B3.22
EPS (TTM)-0.23
EPS (Forward)-0.24
52W Range
0.400068% of range1.570
52W High1.570 USD
52W Low0.4000 USD
Profitability
Gross Margin0.00%
Oper. Margin-1474700.00%
EBITDA Margin0.00%
Profit Margin-51035.71%
ROE-83.89%
ROA-48.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.36M $
CapEx (TTM)—
FCF Margin-687087.50%
FCF Yield-11.12%
Net Debt-10.58M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity45.11
Current Ratio4.29
Quick Ratio4.08
Book Value/Sh0.3690 USD
Cash/Share0.3290 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateOct 26, 2022
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.167 USD
Upside (mean)+166.1%
Target Range3.000 USD – 3.500 USD
$3.000+166.1% to mean$3.500
# Analysts3
Ownership
Shares Out.51.91M
Float25.23M
Insiders21.41%
Institutions46.03%
Short Interest
Short Ratio1.7d
Short % Float1.68%
Short % Out.1.36%
Shares Short705.65K
Short (prev mo.)562.61K
Technical
SMA 501.214 (-2.0%)
SMA 2001.028 (+15.8%)
Beta0.70
S&P 52W Chg18.16%
Avg Vol (30d)353.02K
Avg Vol (10d)461.58K
Technical Indicators
RSI (14)42.5
MACD0.0009
MACD Signal0.0352
MACD Hist.-0.0343
BB Upper1.494 USD
BB Middle1.321 USD
BB Lower1.148 USD
BB Width26.22%
ATR (14)0.0959 USD
Vol Ratio (20d)0.36x